Page last updated: 2024-09-05

lapatinib and atovaquone

lapatinib has been researched along with atovaquone in 2 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(atovaquone)
Trials
(atovaquone)
Recent Studies (post-2010) (atovaquone)
1,9193051,442997100420

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)atovaquone (IC50)
Dihydroorotate dehydrogenase Schistosoma mansoni0.431
Cytochrome bHomo sapiens (human)2.835
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)2.65
Dihydroorotate dehydrogenase (quinone), mitochondrialRattus norvegicus (Norway rat)0.7
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.23

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1

Reviews

2 review(s) available for lapatinib and atovaquone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022